35 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Lymphoma Clinical Trial using Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas.
Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

Peripheral T-Cell Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma.
Gemcitabine; Dexamethasone; Cisplatin; Romidepsin

Leukemia, or Lymphoma Clinical Trial using HSCT; DLI

M.D. Anderson Cancer Center - Recruiting 1 year to 65 years.
- CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
HSCT; DLI

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Hematologic Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Clinical Trial using Stem cell transplantation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases.
Stem cell transplantation

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Lymphoma Clinical Trial using Romidepsin; Ifosfamide; Mesna; Carboplatin; Etoposide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Romidepsin (ISTODAXr) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
Romidepsin; Ifosfamide; Mesna; Carboplatin; Etoposide

Recurrent or Refractory PTCL Clinical Trial using forodesine hydrochloride

Mundipharma K.K. - Recruiting 20 years or older.
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients.
forodesine hydrochloride

Lymphoma Clinical Trial using cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Memorial Sloan-Kettering Cancer Center - Recruiting 13 years to 65 years.
- An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma.
cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Non-Hodgkins Lymphoma, Hodgkins Lymphoma, or Lymphoproliferative Clinical Trial using EBV CTL's; Peripheral Blood Donor

New York Medical College - Recruiting 1 year or older.
- A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Refractory /Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial.
EBV CTL's; Peripheral Blood Donor

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Peripheral T-cell Lymphoma Clinical Trial

Spectrum Pharmaceuticals, Inc - Recruiting N/A or older.
- Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma.

Leukemia, Myelodysplastic Syndrome, or Lymphoma Clinical Trial using CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Memorial Sloan-Kettering Cancer Center - Recruiting 2 years to 70 years.
- Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies.
CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Peripheral T-Cell Lymphoma Clinical Trial using denileukin diftitox (E7777)

Eisai Inc. - Recruiting 20 years to 79 years.
- Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma.
denileukin diftitox (E7777)

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non Clinical Trial using autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma.
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Peripheral T-cell Lymphoma Clinical Trial using Pralatrexate Injection

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy.
Pralatrexate Injection

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study.
alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using carfilzomib; laboratory biomarker analysis

University of Nebraska - Recruiting 19 years or older.
- Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma.
carfilzomib; laboratory biomarker analysis

Lymphoma Clinical Trial using carmustine; cyclophosphamide; etoposide; peripheral blood stem cell transplantation; irradiation therapy; G-CSF; Cytarabine

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 75 years.
- Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma.
carmustine; cyclophosphamide; etoposide; peripheral blood stem cell transplantation; irradiation therapy; G-CSF; Cytarabine

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic Lymph Clinical Trial using alemtuzumab; chemotherapy

University of G”ttingen - Recruiting 61 years to 80 years.
- Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly.
alemtuzumab; chemotherapy

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; fludarabine phosphate

National Cancer Institute (NCI) - Recruiting 18 years to 70 years.
- A Phase I/II Study Of HLA-Matched Mobilized Peripheral Blood Hematopoetic Stem Cell Transplantation For Advanced Mycosis Fungoides/Sezary Using NonMyeloablative Conditioning With Campath-1H.
alemtuzumab; cyclophosphamide; fludarabine phosphate